首页> 外文期刊>Recent patents on regenerative medicine. >Stem Cells in Kidney Transplantation: A Review of Chimerism-Based Protocols to Induce Transplantation Tolerance
【24h】

Stem Cells in Kidney Transplantation: A Review of Chimerism-Based Protocols to Induce Transplantation Tolerance

机译:肾移植中的干细胞:对基于嵌合性的方案促进移植耐受性的综述

获取原文
获取原文并翻译 | 示例
           

摘要

Induction of donor-specific immunological tolerance in order to eliminate the lifelong systemic immunosuppressive therapy and their deleterious side effects as well as to prevent graft loss due to acute or chronic rejection or drug toxicity has been considered the "Holy Grail" of transplantation. The only effective approach of inducing tolerance is combined organ (e.g. kidney) and donor bone marrow transplantation. The hallmark of this protocol is establishment of chimerism and preferentially mixed chimerism using non-meyloablative condition which reduces the risk of GVHD, as well as its feasibility and safety for tolerance induction even in HLA-mismatched kidney graft recipients. The focus of this review is to discuss the last findings of clinical trials mainly from three medical centers as pioneers for designing and implementing tolerance protocols using chimerism-based approaches. Finally, the merits and drawbacks of these protocols are discussed with regard to the feasibility of such protocols for deceased donor grafts and more widespread application in clinical transplantation.
机译:诱导供体特异性免疫耐受性,以消除终身全身免疫抑制治疗及其有害副作用以及由于急性或慢性排斥反应或药物毒性而预防接枝损失已被认为是移植的“圣杯”。诱导耐受性的唯一有效方法是组合器官(例如肾脏)和供体骨髓移植。该协议的标志是使用非魅力的条件建立嵌合体和优先混合逆变,这降低了GVHD的风险,即使在HLA - 错配的肾移植受体中也可进行耐受性和安全性。本综述的重点是讨论主要从三个医疗中心作为使用基于嵌合方法设计和实施公差方案的先驱的临床试验的最后发现。最后,关于这些方案的可行性讨论了这些方案的可行性的可行性和在临床移植中的更广泛应用的可行性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号